In 2022, it was the 51st most commonly prescribed medication in the United States, with more than 12million prescriptions.[17][18] It is available as its acid or in two salts, as either diclofenac sodium or potassium.[15]
Diclofenac ophthalmic is indicated for the treatment of postoperative inflammation in people who have undergone cataract extraction and for the temporary relief of pain and photophobia in people undergoing corneal refractive surgery.[19]
Diclofenac is also available in topical forms and is useful for osteoarthritis but not other types of long-term musculoskeletal pain.[20] Diclofenac may also help with actinic keratosis and with acute pain caused by minor strains, sprains and contusions.[21]
In many countries, eye drops are sold to treat acute and chronic nonbacterial inflammation of the anterior part of the eyes (such as postoperative states).[22] The eye drops have also been used to manage pain for traumatic corneal abrasion.[23]
Diclofenac consumption has been associated with significantly increased vascular and coronary risk in a study including coxib, diclofenac, ibuprofen and naproxen.[27] Upper gastrointestinal complications were also reported.[27]Major adverse cardiovascular events were increased by about a third by diclofenac, chiefly due to an increase in major coronary events.[27] Compared with placebo, of 1000 patients allocated to diclofenac for a year, three more had major vascular events, one of which was fatal.[27] Vascular death is increased significantly by diclofenac.[27]
In October 2020, the US Food and Drug Administration (FDA) required the prescription label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in fetuses that result in low amniotic fluid.[28][29]
Heart
In 2013, a study found major vascular events were increased by about a third by diclofenac, chiefly due to an increase in major coronary events.[27] Compared with placebo, of 1000 people allocated to diclofenac for a year, three more had major vascular events, one of which was fatal.[27] Vascular death was increased by diclofenac (1·65).[27]
Following the identification of increased risks of heart attacks with the selective COX-2 inhibitorrofecoxib in 2004, attention has focused on all the other members of the nonsteroidal anti-inflammatory drug group, including diclofenac. Research results are mixed, with a meta-analysis of papers and reports up to April 2006 suggesting a relative increased rate of heart disease of 1.63 compared to nonusers.[30] Professor Peter Weissberg, medical director of the British Heart Foundation said, "However, the increased risk is small, and many patients with chronic debilitating pain may well feel that this small risk is worth taking to relieve their symptoms". Only aspirin was found not to increase the risk of heart disease; however, this is known to have a higher rate of gastric ulceration than diclofenac. As of January 2015, the MHRA announced that diclofenac would be reclassified as a prescription-only medicine (POM) due to the risk of cardiovascular adverse events.[31]
A subsequent large study of 74,838 Danish users of nonsteroidal anti-inflammatory drugs or coxibs found no additional cardiovascular risk from diclofenac use.[32] A very large study of 1,028,437 Danish users of various nonsteroidal anti-inflammatory drugs or coxibs found the "Use of the nonselective NSAID diclofenac and the selective cyclooxygenase-2 inhibitor rofecoxib was associated with an increased risk of cardiovascular death (odds ratio, 1.91; 95% confidence interval, 1.62 to 2.42; and odds ratio, 1.66; 95% confidence interval, 1.06 to 2.59, respectively), with a dose-dependent increase in risk."[33]
Gastrointestinal complaints are most often noted. Most patients receive a gastro-protective drug as prophylaxis during long-term treatment (misoprostol, ranitidine, or omeprazole).
Liver
Liver damage occurs infrequently, and is usually reversible. Hepatitis may occur rarely without any warning symptoms and may be fatal. Patients with osteoarthritis more often develop symptomatic liver disease than patients with rheumatoid arthritis. If used for the short-term treatment of pain or fever, diclofenac has not been found more hepatotoxic than other nonsteroidal anti-inflammatory drugs.[medical citation needed]
As of December 2009[update], Endo, Novartis, and the US FDA notified healthcare professionals to add new warnings and precautions about the potential for elevation in liver function tests during treatment with all products containing diclofenac sodium.[35]
Cases of drug-induced hepatotoxicity have been reported in the first month but can occur at any time during treatment with diclofenac. Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure. Some of these reported cases resulted in fatalities or liver transplantation.[medical citation needed]
Kidney
Nonsteroidal anti-inflammatory drugs "are associated with adverse renal [kidney] effects caused by the reduction in synthesis of renal prostaglandins"[36] in sensitive persons or animal species, and potentially during long-term use in nonsensitive persons if resistance to side effects decreases with age. However, this side effect cannot be avoided merely by using a COX-2 selective inhibitor because, "Both isoforms of COX, COX-1, and COX-2, are expressed in the kidney...
Mental health
Mental health side effects have been reported. These symptoms are rare but exist in significant enough numbers to include as potential side effects. These include depression, anxiety, irritability, nightmares, and psychotic reactions.[37]
Pharmacology
As with other nonsteroidal anti-inflammatory drugs, the primary mechanism responsible for its anti-inflammatory, antipyretic and analgesic action is thought to be inhibition of prostaglandin synthesis through COX-inhibition.
The main target in the inhibition of prostaglandin synthesis appears to be the transiently expressed prostaglandin-endoperoxide synthase-2 (PGES-2), also known as cycloxygenase-2 (COX-2). That is, diclofenac is partially selective for COX-2. The reported selectivity for COX-2 varies from 1.5 to 30 depending on the source.[38][39][40][41]
The drug may be bacteriostatic via inhibiting bacterial DNA synthesis.[42]
Diclofenac has a relatively high lipid solubility, making it one of the few nonsteroidal anti-inflammatory drugs that are able to enter the brain by crossing the blood-brain barrier.[43] As in the rest of the body, it is thought to exert its effect in the brain through inhibition of COX-2.[43] In addition, it may have effects inside the spinal cord.[44]
Diclofenac may be a unique member of the nonsteroidal anti-inflammatory drugs in other aspects. Some evidence indicates it inhibits the lipoxygenase pathways,[45][46] thus reducing the formation of leukotrienes (also pro-inflammatory autacoids). It also may inhibit phospholipase A2, which may be relevant to its mechanism of action. These additional actions may explain its high potency – it is the most potent NSAID on a broad basis.[47]
Marked differences exist among nonsteroidal anti-inflammatory drugs in their selective inhibition of the two subtypes of cyclooxygenase, COX-1, and COX-2.[48] Drug developers have focused on selective COX-2 inhibition, particularly as a way to minimize the gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. In practice, the use of some COX-2 inhibitors with their adverse effects has led to massive numbers of lawsuits alleging wrongful death by heart attack, yet other significantly COX-selective nonsteroidal anti-inflammatory drugs, such as diclofenac, have been well tolerated by most of the population.[citation needed]
Besides the COX-inhibition, several other molecular targets of diclofenac possibly contributing to its pain-relieving actions have recently been identified. These include:
Blockage of voltage-dependent sodium channels (after activation of the channel, diclofenac inhibits its reactivation, also known as phase inhibition)[49][50]
Positive allosteric modulation of KCNQ- and BK-potassium channels (diclofenac opens these channels, leading to hyperpolarization of the cell membrane)[52][50]
The duration of action (i.e., duration of pain relief) of a single dose is longer (6 to 8 h) than the drug's 1.2–2 h half-life. This could be partly because it persists for over 11 hours in synovial fluids.[53]
History
Diclofenac was first synthesized by Alfred Sallmann and Rudolf Pfister in 1973.[54][55] The name "diclofenac" derives from its chemical name: 2-(2,6-dichloranilino) phenylacetic acid. It was patented in Germany in 1978 by Ciba-Geigy (now Novartis).[56][57] It came into medical use in the United States in 1988.[9]GlaxoSmithKline purchased the rights in 2015.[54] It is available as a generic medication.[9]
Society and culture
Formulations and brand names
Diclofenac formulations are available worldwide under many different brand names.[1]
Voltaren and Voltarol contain the sodium salt of diclofenac. In the United Kingdom, Voltarol can be supplied with either the sodium salt or the potassium salt, while Cataflam, sold in some other countries, is the potassium salt only. However, Voltarol Emulgel contains diclofenac diethylammonium 1.16%, being equivalent to 1% sodium salt. In 2016, Voltarol was one of the biggest selling branded over-the-counter medications sold in Great Britain, with sales of £39.3 million.[58]
In the United States, 1% diclofenac gel was approved by the FDA in 2007 as a prescription drug for the temporary relief of the pain of osteoarthritis of joints in the hands, knees, and feet. In 2020, the FDA approved the gel formulation for nonprescription use.[8]
In January 2015, diclofenac oral preparations were reclassified as prescription-only medicines in the UK. The topical preparations are available without a prescription.[59]
Ecological effects
This section is missing information about environmental buildup, wastewater; try PMID27649472. Please expand the section to include this information. Further details may exist on the talk page.(December 2022)
Use of diclofenac for animals is controversial due to toxicity when eaten by scavenging birds that eat dead animals;[60][61] the medication has been banned for veterinary use in several countries.[62][63]
Use of diclofenac in animals has been reported to have led to a sharp decline in the vulture population in the Indian subcontinent – a 95% decline by 2003[64] and a 99.9% decline by 2008. The mechanism is presumed to be kidney failure;[65] however, toxicity may be due to direct inhibition of uric acid secretion in vultures.[66] Vultures eat the carcasses of livestock that have been administered veterinary diclofenac, and are poisoned by the accumulated chemical,[67] as vultures do not have a particular enzyme to break down diclofenac. At a meeting of the National Wildlife Board in March 2005, the Government of India announced it intended to phase out the veterinary use of diclofenac.[68]Meloxicam is a safer alternative to replace use of diclofenac.[69] It is more expensive than diclofenac, but the cost is dropping[when?] as more pharmaceutical companies are beginning to manufacture it.[citation needed]
Steppe eagles have the same vulnerability to diclofenac as Old World vultures and are therefore at a similar risk from its effects.[70] Diclofenac has been shown also to harm freshwater fish species such as rainbow trout.[71][72][73][74] In contrast, New World vultures, such as the turkey vulture, can tolerate at least 100 times the level of diclofenac that is lethal to Gyps species.[75]
"The loss of tens of millions of vultures over the last decade has had major ecological consequences across the Indian subcontinent that pose a potential threat to human health. In many places, populations of feral dogs have increased sharply from the disappearance of Gyps vultures as the main scavenger of wild and domestic ungulate carcasses. Associated with the rise in dog numbers is an increased risk of rabies"[69] and casualties of almost 50,000 people.[76] The Government of India cites this as one of the major consequences of a vulture species extinction.[68] A major shift in the transfer of corpse pathogens from vultures to feral dogs and rats could lead to a disease pandemic, causing millions of deaths in a crowded country like India, whereas vultures' digestive systems safely destroy many species of such pathogens. Vultures are long-lived and slow to breed. They start breeding only at the age of six and only 50% of their young survive. Even if the government ban is fully implemented, it will take many years to revive the vulture population.[77]
Despite the vulture crisis, diclofenac remains available in other countries including many in Europe.[78] It was controversially approved for veterinary use in Spain in 2013 and continues to be available, despite Spain being home to around 90% of the European vulture population and an independent simulation showing that the drug could reduce the population of vultures by 1–8% annually. Spain's medicine agency presented simulations suggesting that the number of deaths would be quite small.[79][80] A paper published in 2021 identified the first authenticated death of a vulture from diclofenac in Spain, a cinereous vulture.[61][81]
Diclofenac is on the European Union's watch list because it pollutes the Baltic Sea. When the substance enters freshwater, it has an environmental impact and is considered more difficult to remove in wastewater treatment plants than, for example, ibuprofen.[82] Harmful residues have been found in blue mussels and fish, among others, where it has been found to cause damage to internal organs such as the gills, kidneys and liver.[83]
Veterinary use
Diclofenac is used for livestock; such use was responsible for the Indian vulture crisis, during which in a few years 95% of the country's vulture population was killed, and in many countries, agricultural use is now forbidden.[60][61][62][63]
Diclofenac is approved as a veterinary medication in some countries[60][61][62][63] for the treatment of pets as well as in livestock. In some species of birds, diclofenac causes accumulation of uric acid crystals in internal organs—especially the liver and kidneys—resulting in visceral gout, as well as cellular damage and necrosis.[84] In South Asia in the 2000s, vulture populations were decimated after feeding on carcasses of livestock that had been treated with diclofenac.[79]
References
^ abc"Diclofenac". Drugs.com. Archived from the original on 22 December 2018. Retrieved 22 December 2018.
^Chung CH (2017). "The use of Injectable Nonsteroidal Anti-Inflammatory Drugs in Local Accident & Emergency Practice". Hong Kong Journal of Emergency Medicine. 9 (2): 65–71. doi:10.1177/102490790200900201. S2CID74032271.
^Dutta NK, Mazumdar K, Dastidar SG, Park JH (2007). "Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice". International Journal of Antimicrobial Agents. 30 (4): 336–340. doi:10.1016/j.ijantimicag.2007.04.016. PMID17644321.
^"Naclof, oogdruppels 1 mg/ml"(PDF). Laboratoires THEA. Netherlands: Netherlands Medicines Authority MEB. Archived from the original(PDF) on 4 March 2016 – via Medicines Information Bank.
^Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S (May 2006). "Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk". Arthritis and Rheumatism. 54 (5): 1378–1389. doi:10.1002/art.21887. PMID16645966. S2CID2082359.
^FitzGerald GA, Patrono C (August 2001). "The coxibs, selective inhibitors of cyclooxygenase-2". The New England Journal of Medicine. 345 (6): 433–442. doi:10.1056/NEJM200108093450607. PMID11496855.
^Dastidar SG, Ganguly K, Chaudhuri K, Chakrabarty AN (April 2000). "The anti-bacterial action of diclofenac shown by inhibition of DNA synthesis". International Journal of Antimicrobial Agents. 14 (3): 249–251. doi:10.1016/S0924-8579(99)00159-4. PMID10773497.
^Gan TJ (July 2010). "Diclofenac: an update on its mechanism of action and safety profile". Current Medical Research and Opinion. 26 (7): 1715–1731. doi:10.1185/03007995.2010.486301. PMID20470236.
^Ku EC, Lee W, Kothari HV, Scholer DW (April 1986). "Effect of diclofenac sodium on the arachidonic acid cascade". The American Journal of Medicine. 80 (4B): 18–23. doi:10.1016/0002-9343(86)90074-4. PMID3085488.
^Scholer DW, Ku EC, Boettcher I, Schweizer A (April 1986). "Pharmacology of diclofenac sodium". The American Journal of Medicine. 80 (4B): 34–38. doi:10.1016/0002-9343(86)90077-x. PMID3085490.
^Cryer B, Feldman M (May 1998). "Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs". The American Journal of Medicine. 104 (5): 413–421. doi:10.1016/S0002-9343(98)00091-6. PMID9626023.
^Fei XW, Liu LY, Xu JG, Zhang ZH, Mei YA (August 2006). "The non-steroidal anti-inflammatory drug, diclofenac, inhibits Na(+) current in rat myoblasts". Biochemical and Biophysical Research Communications. 346 (4): 1275–1283. doi:10.1016/j.bbrc.2006.06.034. PMID16806078.
^ abGwanyanya A, Macianskiene R, Mubagwa K (October 2012). "Insights into the effects of diclofenac and other non-steroidal anti-inflammatory agents on ion channels". The Journal of Pharmacy and Pharmacology. 64 (10): 1359–1375. doi:10.1111/j.2042-7158.2012.01479.x. PMID22943167.
^Ortiz MI, Torres-López JE, Castañeda-Hernández G, Rosas R, Vidal-Cantú GC, Granados-Soto V (March 2002). "Pharmacological evidence for the activation of K(+) channels by diclofenac". European Journal of Pharmacology. 438 (1–2): 85–91. doi:10.1016/S0014-2999(02)01288-8. PMID11906715.
^Fowler PD, Shadforth MF, Crook PR, John VA (1983). "Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis". European Journal of Clinical Pharmacology. 25 (3): 389–394. doi:10.1007/BF01037953. PMID6628528. S2CID9803699.
^Fischer J (2006). Analogue-based drug discovery. Wiley-VCH. p. 517. ISBN978-3-527-31257-3.
^DE 1793592, Pfister R, Sallmann A, "Process for the production of new substituted phenylacetic acids", issued 26 January 1978, assigned to Ciba Geigy AGArchived 24 April 2023 at the Wayback Machine
^ abcdMoreno-Opo R, Carapeto R, Casimiro R, Rubio C, Muñoz B, Moreno I, et al. (2021). "The veterinary use of diclofenac and vulture conservation in Spain: Updated evidence and socio-ecological implications". The Science of the Total Environment. 796: 148851. Bibcode:2021ScTEn.79648851M. doi:10.1016/j.scitotenv.2021.148851. PMID34271379.
^Naidoo V, Swan GE (2009). "Diclofenac toxicity in Gyps vulture is associated with decreased uric acid excretion and not renal portal vasoconstriction". Comparative Biochemistry and Physiology. Toxicology & Pharmacology. 149 (3): 269–274. doi:10.1016/j.cbpc.2008.07.014. hdl:2263/13907. PMID18727958.
^ ab"Saving the Vultures from Extinction" (Press release). Press Information Bureau, Government of India. 16 May 2005. Archived from the original on 20 December 2005. Retrieved 12 May 2006.